Physician profile
Christopher R Buttelman
NPI 1437128840
$2,729.37
in general payments reported to CMS, 2019-2025
26 companies · $312 in 2025
The $312 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2020: $66.73 · 2021: $363 · 2022: $576 · 2023: $641 · 2024: $611 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,564.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $353.92 | 2021-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $288.16 | 2022-2024 | Mounjaro, Zepbound |
| Pfizer INC. | $234.83 | 2019-2023 | |
| Exact Sciences Corporation | $215.72 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $195.37 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $183.21 | 2021-2024 | Farxiga, Airsupra, Breztri |
| E.R. Squibb & Sons, L.L.C. | $164.47 | 2019-2024 | Eliquis |
| Angiodynamics, INC. | $159.66 | 2022 | |
| Novartis Pharmaceuticals Corporation | $148.43 | 2019-2025 | |
| Abbvie INC. | $117.28 | 2022-2024 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $96.51 | 2022-2023 | Austedo, Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $90.60 | 2021-2022 | |
| Abbott Laboratories | $87.51 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $56.02 | 2022-2024 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $49.99 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $43.67 | 2022-2023 | Quviviq |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.78 | 2025 | Lifevest |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.91 | 2024-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $31.91 | 2025 | Voquezna |
| Coloplast Corp | $27.85 | 2023 | Speedicath |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.25 | 2025 | Jardiance |
| Almatica Pharma LLC | $26.22 | 2023 | Loreev Xr |
| Novo Nordisk INC | $17.66 | 2023 | Ozempic, Rybelsus |
| Avanir Pharmaceuticals, INC. | $16.85 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $16.16 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $12.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Buttelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.